size and dose spread assumptions. CONCLUSION: Cost of GH waste can be an important consideration when evaluating GH devices.

**PDB18**

**COMPARISON OF RESOURCES UTILIZATION (RU) AND COST IN DRUG NAÏVE TYPE 2 DIABETES (T2D) PATIENTS TREATED WITH ROSIGLITAZONE (RSG) VS. SULFONYLUREA (SU) MONOTHERAPY**

Duh MT1, Gosselin A2, Beaulieu N1, Arana LM1, Arondelak B1

1Analysis Group, Inc, Boston, MA, USA, 2Groupe d’Analyse, Ltee, Montréal, QC, Canada.

OBJECTIVE: The objective of this study was to compare RU and costs for drug naïve patients treated with RSG versus SU first-line monotherapy using real-world claims data. METHODS: Based on medical, pharmacy, and disability insurance claims data between October 2001 and December 2004, patients with a diagnosis T2D who were newly initiated on an OAD, between October 2001 and December 2004, patients with a diagnosis T2D who were newly initiated on an OAD, aged ≥18 years old, and had ≥60 days of uninterrupted treatment were analyzed. Frequency of inpatient and outpatient visits and average direct (inpatient, outpatient, and pharmacy) and indirect (work-loss) costs were compared between the RSG and SU groups.

RESULTS: A total of 3377 RSG and 11,778 SU patients met the inclusion criteria with RSG patients being younger (63.8 vs. 66.9 years, p < 0.001) with less co-morbidities (Charlson co-morbidity index 0.95 vs. 1.23, p < 0.001) at baseline. During treatment, RSG patients incurred fewer inpatient visits (0.47 vs. 0.77 visits per patient per year (PPPY), p < 0.001), outpatient visits (17.0 vs. 17.9 visits PPPY, p < 0.001), and hospital days (1.6 vs. 2.9 days PPPY, p < 0.001) than SU patients. The total direct medical cost was lower in the RSG group ($1065 vs. $1315 per patient per month (PPPM), p < 0.001) than the SU group, including lower inpatient and outpatient cost ($717 vs. $1046 PPPM, p < 0.001) but higher pharmacy cost ($348 vs. $270 PPPM, p < 0.001). After taking into account the indirect work-loss cost, the total direct and indirect cost was significantly lower in the RSG group ($1103 vs. $1355 PPPM, p < 0.001). Multivariate analysis controlling for age, gender, co-morbidities, and other covariates confirmed that the RSG group was associated with a significantly lower total cost than the SU group (cost difference: $92.75 PPPM, p = 0.012). CONCLUSION: This observational study of over 15,000 patients initiated on first-line monotherapy shows that RSG patients incur significantly lower resource utilization and costs than SU patients, outweighing higher pharmacy cost.

**PDB19**

**ECONOMIC EVALUATION OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF SHORT CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA)**

Christensen T1, Buckland AG2, Bentley A3, Djuurhus C1, Wing C1

1Novo Nordisk A/S, Bagsvaerd, Denmark, 2Abacus International, Bicester, UK.

OBJECTIVE: Current treatment options for short children born small for gestational age (SGA) are limited; however, the growth hormone somatropin (Norditropin) has been shown to normalise height in childhood and adolescence compared to no treatment. The aim of this study was to establish whether somatropin (Norditropin) was a cost-effective treatment option for short children born SGA compared to no treatment. METHODS: A decision tree model was used to calculate the relative costs and health benefits associated with somatropin (Norditropin) treatment vs no treatment over the lifetime of short children born SGA. The analysis was undertaken from a UK National Health Service (NHS) perspective; unit costs (GBP; 2007) were sourced from relevant UK health care providers. Clinical effectiveness data were taken from a long-term, multi-centre, double-blind, randomised clinical trial comparing the effects of somatropin (Norditropin) to no treatment. Utility data was derived from a recent UK-based study which assessed the relationship between short stature and HRQoL. Sensitivity analyses were conducted to assess the degree of uncertainty surrounding the data. RESULTS: Over a patient’s lifetime, somatropin (Norditropin) $(0.033 mg/ kg/day)$ was associated with an additional 2.74 quality-adjusted life years (QALYs) and an incremental cost of GBP73,545 compared with no treatment. As a result, somatropin (Norditropin) was associated with an incremental cost per QALY of GBP26,794 compared with no treatment. Probabilistic sensitivity analysis, in which all parameters within the model were varied, showed that there was a high probability that somatropin (Norditropin) was cost effective compared to no treatment, based on a willingness to pay threshold of GBP30,000 per QALY. CONCLUSION: Based on a willingness to pay threshold of GBP30,000 per QALY, somatropin (Norditropin) is a cost-effective treatment strategy for short children born SGA, providing substantial incremental health benefits at an additional cost.

**PDB20**

**COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE 1 DIABETES MELLITUS (T1DM) IN THE CANADIAN PAYER SETTING: MODELING ANALYSIS USING A RANDOMIZED CONTROLLED TRIAL**

Minshall ME1, Tunis SL1, Conner C1, McCormick JP1, Kapor J4, Groleau D1

1IMS Health, Noblesville, IN, USA, 2Novo Nordisk, Princeton, NJ, USA, 3McKesson Phase 4 Solutions, Toronto, ON, Canada, 4Novo Nordisk, Mississauga, ON, Canada

OBJECTIVE: Insulin detemir represents a class of long-acting soluble insulin analogues intended to address basal insulin requirements for patients with diabetes. Because direct acquisition costs of newer medications are higher than older insulin treatments, payers are interested in their long-term value. This study was conducted to quantify the long-term cost-effectiveness of insulin detemir compared to intermediate-acting NPH insulin for the treatment of T1DM in Canada. METHODS: The CORE Diabetes Model was used to project lifetime clinical and economic outcomes for T1DM patients on insulin detemir versus NPH insulin. A slight advantage for insulin detemir in HbA1c (+0.12%) and significant reductions in major (25%) and minor (25%) hypoglycemic events costs for detemir (CAN$765) vs. NPH (CAN$1965) were observed. Quality-adjusted life years (QALYs) increased by 0.344 years (discounted) with detemir and were largely due to decreased hypoglycemic events. The resulting incremental cost-effectiveness ratio (ICER) for detemir vs. NPH was CAN$26,794 compared with no treatment. Probabilistic sensitivity analyses were conducted to address the lifetime horizon. A 61% reduction in major hypoglycemic events costs for detemir (208,403 for insulin detemir and 208,551 for NPH using a lifetime horizon. A 61% reduction in major hypoglycemic events costs for detemir (CAN$765) vs. NPH (CAN$1965) were observed. Quality-adjusted life years (QALYs) increased by 0.344 years (discounted) with detemir and were largely due to decreased hypoglycemic events. The resulting incremental cost-effectiveness ratio (ICER) for detemir vs. NPH was CAN$34,418/QALY. CONCLUSION: The ICER obtained in this analysis provides evidence for the long-term cost-effectiveness of insulin detemir compared to NPH in T1DM and is consistent with current Canadian standards. The overall value of detemir was driven primarily by its favorable impact upon...
hypoglycemic events as well as lower costs in treating major hypoglycemic events.

OBJECTIVE: Insulin detemir represents a class of long-acting soluble insulin analogues intended to address basal insulin requirements for patients with diabetes. Because direct acquisition costs of newer medications are higher than older insulin treatments, payers are interested in their long-term value. This study was conducted to quantify the long-term cost-effectiveness of insulin detemir compared to intermediate-acting NPH insulin for the treatment of T2DM in Canada. METHODS: The CORE Diabetes Model was used to project lifetime clinical and economic outcomes for T2DM patients on insulin detemir versus NPH insulin. A slight advantage for insulin detemir in HbA1c (-0.18%) and significant reductions in major (93%) and minor (73%) hypoglycemic events were modeled. These clinical assumptions, as well as cohort characteristics (baseline age and HbA1c of 59 and 8.3%, respectively), transition probabilities, utilities, dis-utilities, direct treatment and complication costs (from a Canadian provincial payer perspective) were derived from recent published literature and on-line sources. Both clinical and economic outcomes were discounted at 5% per annum. RESULTS: Average total direct costs per patient were CANS$74,227 for insulin detemir and CANS$68,509 for NPH using a lifetime horizon. An 87% reduction in major hypoglycemic events costs for detemir (CANS$289) vs. NPH (CANS$2,444) were observed. Quality-adjusted life years (QALYs) increased by 0.304 years (discounted) with detemir and were largely due to decreased hypoglycemic events. The resulting incremental cost-effectiveness ratio (ICER) for detemir vs. NPH was CANS$18,840/QALY. CONCLUSION: The ICER obtained in this analysis provides evidence for the long-term cost-effectiveness of insulin detemir compared to NPH in T2DM and is consistent with current Canadian standards. The overall value of detemir was driven primarily by its favorable impact upon hypoglycemic events as well as lower costs in treating major hypoglycemic events.

OBJECTIVE: To review the projected long term costs and outcomes of continuous subcutaneous insulin infusion (CSI) compared with multiple daily injections (MDI) of insulin in adult type 1 diabetes mellitus (T1DM) patients in Canada. METHODS: A valid health economic model was used to determine the incremental cost-effectiveness ratio (ICER) of CSI compared with MDI among adult patients with T1DM from a Canadian provincial government perspective. The primary input variable was change in HbA1c and the model was adjusted for diabetes-related complications. The average annual costs for CSII and MDI were CND $6,347.18 and CND $4,650.20, respectively. The cost of pump, procedures, complications, and optimal drug therapy were derived from Canadian-specific sources and other published data. A 60-year time horizon and a discount rate of 5% per annum was assumed. The analyses demonstrated that CSII is a cost-effective treatment option for all four countries when compared to MDI for adult T1DM patients. RESULTS: Treatment with CSII vs. MDI was associated with an improvement in quality-adjusted life years (QALYS) of 1.2% improvement for CSII vs. MDI. A series of Markov constructs simulated the progression of diabetes-related complications. The average annual costs for CSII compared with MDI were locally derived (a 7–8 year pump life was assumed). The costs of optimal drug therapy, procedures and complications were derived from published federal and industry specific data. A 60-year time horizon was used for all analyses and a discount rate of either 3.0% (USA, UK) or 5.0% (CAN, Australia) per annum on costs and clinical outcomes were used. COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION vs. MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS: A CANADIAN PERSPECTIVE

St. Charles M1, Sadri H2, Minshall M1
1IMS Health, Noblesville, IN, USA, 2Medtronic of Canada Ltd, Mississauga, ON, Canada

OBJECTIVE: To project long term costs and outcomes of continuous subcutaneous insulin infusion (CSI) compared with multiple daily injections (MDI) of insulin in adult type 1 diabetes mellitus (T1DM) patients in Canada. METHODS: A valid health economic model was used to determine the incremental cost-effectiveness ratio (ICER) of CSI compared with MDI among adult patients with T1DM from a Canadian provincial government perspective. The primary input variable was change in HbA1c and the model was adjusted for diabetes-related complications. The average annual costs for CSII and MDI were CND $6,347.18 and CND $4,650.20, respectively. The cost of pump, procedures, complications, and optimal drug therapy were derived from Canadian-specific sources and other published data. A 60-year time horizon and a discount rate of 5% per annum was assumed. The analyses demonstrated that CSII is a cost-effective treatment option for all four countries when compared to MDI for adult T1DM patients. RESULTS: Treatment with CSII vs. MDI was associated with an improvement in quality-adjusted life expectancy of 0.655 vs. 0.629 for CSII vs. MDI. The cumulative incidence of end-stage renal disease (ESRD) was reduced by 20% (relative risk [RR] = 0.839); with a NNT of 46 patients. Setting the willingness to pay at the accepted level for each country (USD$50,000/QALY, CAN$50,000/QALY, AUS$76,000/QALY and €30,000/QALY), the analyses demonstrated that CSII is a cost-effective treatment option for all four countries when compared to MDI for adult T1DM patients.

COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS: AN INTERNATIONAL COMPARISON

Graham C1, Lynch P1, St. Charles M2, Minshall M2
1Medtronic Diabetes, Northridge, CA, USA, 2IMS Health, Noblesville, IN, USA

OBJECTIVE: To review the projected long term costs and outcomes of continuous subcutaneous insulin infusion (CSI) compared with multiple daily injections (MDI) of insulin in adult type 1 diabetes mellitus (T1DM) patients in the USA, Canada (CAN), Australia (AUS), and the United Kingdom (UK). METHODS: A valid health economic model was used to determine the incremental cost-effectiveness ratio (ICER) of CSI compared with MDI among adult patients with T1DM for all four countries. The primary input variable was change in HbA1c and was assumed to be a −1.2% improvement for CSI vs. MDI. A series of Markov constructs simulated the progression of diabetes-related complications. The average annual costs for CSII compared with MDI were locally derived (a 7–8 year pump life was assumed). The costs of optimal drug therapy, procedures and complications were derived from published federal and industry specific data. A 60-year time horizon was used for all analyses and a discount rate of either 3.0% (USA, UK) or 5.0% (CAN, Australia) per annum on costs and clinical outcomes were used. RESULTS: Treatment with CSII vs. MDI was associated with an improvement in quality-adjusted life years (QALYS) gained of 1.061, 0.655, 0.467 and 0.760 for adults in the USA, CAN, AUS and the UK, respectively. ICERs were USD$16,992, CAN$23,797, AUS$74,147 and €25,648 per QALY gained for CSII vs. MDI in adults with T1DM. Improved glycemic control from CSII treatment led to a lower incidence of diabetes complications; most prominently for proliferative diabetic retinopathy, end-stage renal disease and peripheral vascular disease. CONCLUSION: Setting the willingness to pay at the accepted level for each country (USD$50,000/QALY, CAN$50,000/QALY, AUS$76,000/QALY and €30,000/QALY), the analyses demonstrated that CSII is a cost-effective treatment option for all four countries when compared to MDI for adult T1DM patients.